
Effect of High Blood Pressure and Antihypertensive Treatment on Brain Functioning in Children
HypertensionHigh blood pressure, or hypertension, affects up to 10% of minority children and adolescents. Although complications of high blood pressure, such as stroke and heart attack, are uncommon in childhood, high blood pressure-related organ damage can occur at a young age. Studies with young adults have indicated that high blood pressure can affect the central nervous system, resulting in deficits in brain function. However, more research is necessary to confirm the association between neurocognitive deficits and high blood pressure in children and to determine if these deficits are reversible with treatment. This study will determine whether high blood pressure in children and adolescents has subtle effects on learning, attention, and concentration. The study will also determine the effect of an antihypertensive treatment plan, involving a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication, on brain function in children and adolescents receiving treatment for high blood pressure.

Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension...
Pulmonary HypertensionOpen label extension study to the pivotal efficacy study to assess the safety of sildenafil citrate in patients with pulmonary arterial hypertension

To Yield Further Information On The Efficacy And Safety Of Viagra Among Subjects With Arterial Hypertension...
ImpotenceHypertensionTo assess changes with respect to Erectile Dysfunction in subjects treated with Viagra and antihypertensive therapy.

The Effect of Statin Use on Vascular Function in Hypertensive Subjects
HypertensionThis research is being done to find if treatment with atorvastatin, a drug that reduces cholesterol, improves the function of blood vessels among people with high blood pressure. Adults with mildly high blood pressure, or who are taking medication for high blood pressure but are otherwise healthy may join, with the approval of their health care provider. The study period is 14-17 weeks. Approximately 50 to 60 subjects will take part in the study.

Olmesartan Medoxomil in Hypertension and Renal Impairment
Essential HypertensionRenal ImpairmentThis is a study in hypertensive patients with mild to moderate renal impairment. The antihypertensive efficacy of olmesartan medoxomil is compared to losartan.

Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled...
HypertensionThis study will test the effectiveness and safety of a combination treatment in patients whose blood pressure is not controlled with a single medication

A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years...
HypertensionDrugs used to treat hypertension in adults should also be effective in treating high blood pressure in infants and children. This study will test the safety and efficacy of valsartan in lowering blood pressure in children 1 - 5 years old whose parents grant permission to participate.

Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With...
HypertensionDyslipidemiaPatients with mild to moderate hypertension, dyslipidemia (imbalanced blood lipids) and decreased vascular dilatation, receiving a cholesterol lowering diet were given either valsartan or fluvastatin for 8 weeks. At week 8 all patients were administered a combination treatment with valsartan 160 mg and fluvastatin 80 mg.

Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients....
HypertensionA study to compare the effects of Diovan or Atenolol taken for 12 weeks on platelet function of patients who have mild to moderately severe hypertension

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With...
GlaucomaOpen-Angle1 moreThe purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.